Biogen Inc stock page - price, fundamentals, dividends - iOCharts

Ticker
BIIB

Price
210.63
Stock movement up
+6.69 (3.28%)
Company name
Biogen Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
30.85B
Ent value
41.49B
Price/Sales
2.85
Price/Book
2.75
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
21.28
Forward P/E
13.15
PEG
23.64
EPS growth
20.50%
1 year return
-39.63%
3 year return
-3.77%
5 year return
-4.98%
10 year return
4.88%
Last updated: 2022-07-01

DIVIDENDS

BIIB does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E21.28
Price to OCF10.17
Price to FCF11.13
Price to EBITDA13.67
EV to EBITDA18.39

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.85
Price to Book2.75
EV to Sales3.83

FINANCIALS

Per share

Loading...
Per share data
Current share count146.45M
EPS (TTM)0.10
FCF per share (TTM)0.19

Income statement

Loading...
Income statement data
Revenue (TTM)10.82B
Gross profit (TTM)8.43B
Operating income (TTM)2.48B
Net income (TTM)1.45B
EPS (TTM)0.10
EPS (1y forward)16.02

Margins

Loading...
Margins data
Gross margin (TTM)77.95%
Operating margin (TTM)22.90%
Profit margin (TTM)13.40%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.75B
Net receivables2.02B
Total current assets7.92B
Goodwill5.76B
Intangible assets2.15B
Property, plant and equipment0.00
Total assets23.61B
Accounts payable398.70M
Short/Current long term debt7.59B
Total current liabilities3.95B
Total liabilities12.39B
Shareholder's equity11.22B
Net tangible assets3.33B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)3.03B
Capital expenditures (TTM)260.20M
Free cash flow (TTM)2.77B
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity12.92%
Return on Assets6.14%
Return on Invested Capital7.84%
Cash Return on Invested Capital14.99%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open205.37
Daily high210.75
Daily low203.96
Daily Volume748K
All-time high438.43
1y analyst estimate237.96
Beta0.42
EPS (TTM)0.10
Dividend per share-
Ex-div date-
Next earnings date20 Jul 2022

Downside potential

Loading...
Downside potential data
BIIBS&P500
Current price drop from All-time high-51.96%-20.19%
Highest price drop-90.00%-56.47%
Date of highest drop30 Dec 19949 Mar 2009
Avg drop from high-33.25%-11.36%
Avg time to new high35 days12 days
Max time to new high1835 days1805 days
COMPANY DETAILS
BIIB (Biogen Inc) company logo
Marketcap
30.85B
Marketcap category
Large-cap
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Employees
9610
Investor relations
SEC filings
CEO
Josephine Price
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
In the immediate aftermath of the Supreme Court's decision to overturn nationwide protections for abortion, Cambridge-based Biogen Inc. says it will begin paying for travel for its employees to access...
June 29, 2022
Nicole Murphy, Head of Pharmaceutical Operations & Technology, explains that most of a company’s environmental impact comes from its supply chain. In our quest to go fossil fuel free, we are partne...
June 28, 2022
Biotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delive...
June 27, 2022
Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company...
June 24, 2022
Machelle Sanders, secretary of the Department of Commerce for North Carolina, climbed the corporate ranks before taking charge of the state's thriving economic development prospects. Now, she must kee...
June 23, 2022
Armany is a rising junior at Northeastern University majoring in electrical and computer engineering who developed a passion for science during his time as a Biogen Community Lab student and as a R...
June 22, 2022
CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solu...
June 22, 2022
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
June 21, 2022
Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office h...
June 21, 2022
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
June 17, 2022
Next page